Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.
BRCA1
BRCA2
Breast cancer
Familial
Mammography
Young
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
10
09
2018
revised:
24
12
2018
accepted:
16
01
2019
entrez:
23
4
2019
pubmed:
23
4
2019
medline:
23
4
2019
Statut:
ppublish
Résumé
Many women who are at increased risk of breast cancer due to a mother or sister diagnosed with breast cancer aged under 40 do not currently qualify for surveillance before 40 years of age. There are almost no available data to assess whether mammography screening aged 35-39 years would be effective in this group, in terms of detection of breast cancer at an early stage or cost effective. A cohort screening study (FH02) with annual mammography was devised for women aged 35-39 to assess the sensitivity and screening performance and potential survival of women with identified tumours. 2899 women were recruited from 12/2006-12/2015. These women underwent 12,086 annual screening mammograms and were followed for 13,365.8 years. A total of 55 breast cancers in 54 women occurred during the study period (one bilateral) with 50 cancers (49 women) (15 CIS) adherent to the screening. Eighty percent (28/35) of invasive cancers were ≤ 2 cm and 80% also lymph node negative. Invasive cancers diagnosed in FH02 were significantly smaller than the comparable (POSH-unscreened prospective) study group (45% (131/293) ≤ 2 cm in POSH vs 80% (28/35) in FH02 p < 0.0001), and were less likely to be lymph-node positive (54% (158/290, 3 unknown) in POSH vs 20% (7/35) in FH02: p = 0.0002. Projected and actual survival were also better than POSH. Overall radiation dose was not higher than in an older screened population at mean dose on study per standard sized breast of 1.5 mGy. Mammography screening aged 35-39 years detects breast cancer at an early stage and is likely to be as effective in reducing mortality as in women at increased breast cancer risk aged 40-49 years.
Sections du résumé
BACKGROUND
BACKGROUND
Many women who are at increased risk of breast cancer due to a mother or sister diagnosed with breast cancer aged under 40 do not currently qualify for surveillance before 40 years of age. There are almost no available data to assess whether mammography screening aged 35-39 years would be effective in this group, in terms of detection of breast cancer at an early stage or cost effective.
METHODS
METHODS
A cohort screening study (FH02) with annual mammography was devised for women aged 35-39 to assess the sensitivity and screening performance and potential survival of women with identified tumours.
FINDINGS
RESULTS
2899 women were recruited from 12/2006-12/2015. These women underwent 12,086 annual screening mammograms and were followed for 13,365.8 years. A total of 55 breast cancers in 54 women occurred during the study period (one bilateral) with 50 cancers (49 women) (15 CIS) adherent to the screening. Eighty percent (28/35) of invasive cancers were ≤ 2 cm and 80% also lymph node negative. Invasive cancers diagnosed in FH02 were significantly smaller than the comparable (POSH-unscreened prospective) study group (45% (131/293) ≤ 2 cm in POSH vs 80% (28/35) in FH02 p < 0.0001), and were less likely to be lymph-node positive (54% (158/290, 3 unknown) in POSH vs 20% (7/35) in FH02: p = 0.0002. Projected and actual survival were also better than POSH. Overall radiation dose was not higher than in an older screened population at mean dose on study per standard sized breast of 1.5 mGy.
INTERPRETATION
CONCLUSIONS
Mammography screening aged 35-39 years detects breast cancer at an early stage and is likely to be as effective in reducing mortality as in women at increased breast cancer risk aged 40-49 years.
Identifiants
pubmed: 31008449
doi: 10.1016/j.eclinm.2019.01.005
pii: S2589-5370(19)30005-7
pmc: PMC6472550
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-46Références
Eur Radiol. 2010 Nov;20(11):2547-56
pubmed: 20582702
Cancer Prev Res (Phila). 2014 Oct;7(10):993-1001
pubmed: 25047362
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Eur J Cancer. 2006 Jul;42(10):1385-90
pubmed: 16750910
N Engl J Med. 2008 Oct 16;359(16):1675-84
pubmed: 18832239
Ann Surg Oncol. 2017 Jan;24(1):59-63
pubmed: 27527719
Fam Cancer. 2014 Mar;13(1):13-21
pubmed: 23733252
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2123-31
pubmed: 19567506
Br J Radiol. 2016;89(1058):20150831
pubmed: 26654386
J Epidemiol Biostat. 2001;6(5):365-9; discussion 371-5
pubmed: 11822726
Br J Radiol. 2016;89(1059):20150960
pubmed: 26795734
Cancer. 1997 Dec 1;80(11):2091-9
pubmed: 9392331
Lancet. 2005 May 21-27;365(9473):1769-78
pubmed: 15910949
Int J Epidemiol. 1991 Dec;20(4):852-8
pubmed: 1800422
N Engl J Med. 2005 Oct 27;353(17):1773-83
pubmed: 16169887
Lancet Oncol. 2010 Dec;11(12):1127-34
pubmed: 21093374
Biometrics. 1984 Mar;40(1):1-14
pubmed: 6733223
BMJ. 1995 Nov 4;311(7014):1189-93
pubmed: 7488893
Int J Cancer. 2012 Jul 15;131(2):417-25
pubmed: 21898384
J Med Genet. 2000 Mar;37(3):203-9
pubmed: 10699057
Lancet Oncol. 2015 Sep;16(9):1123-1132
pubmed: 26206144
J Med Genet. 2003 Nov;40(11):807-14
pubmed: 14627668
Br J Cancer. 2005 Mar 14;92(5):955-60
pubmed: 15726103
Lancet. 2006 Dec 9;368(9552):2053-60
pubmed: 17161727
J Med Screen. 1995;2(4):180-5
pubmed: 8719145
Am J Hum Genet. 1991 Feb;48(2):232-42
pubmed: 1990835
BMC Cancer. 2007 Aug 15;7:160
pubmed: 17697367
JAMA Oncol. 2018 Apr 01;4(4):476-482
pubmed: 29346471
J Med Screen. 2006;13(4):177-82
pubmed: 17217606
J Med Screen. 2012 Mar;19(1):14-9
pubmed: 22355181
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
J Med Genet. 2017 Feb;54(2):111-113
pubmed: 27794048